NCT02200718 - A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2020

Primary Completion Date

November 9, 2024

Study Completion Date

November 9, 2024

Conditions

Multiple Sclerosis

Interventions

BIOLOGICAL

NeuroVax

NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA BV5S2, BV6S5 BV13S1

BIOLOGICAL

IFA Incomplete Freund's Adjuvant

IFA Incomplete Freund's Adjuvant is a vaccine adjuvant composed of a light mineral oil and a surfactant system designed to make a water-in-oil emulsion

Trial Locations (1)

92129

CRO, San Diego